GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Samil Pharmaceutical Co Ltd (XKRX:000520) » Definitions » Capex-to-Operating-Income

Samil Pharmaceutical Co (XKRX:000520) Capex-to-Operating-Income : 1.03 (As of Jun. 2024)


View and export this data going back to 1985. Start your Free Trial

What is Samil Pharmaceutical Co Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Samil Pharmaceutical Co's Capital Expenditure for the three months ended in Jun. 2024 was ₩-1,137.43 Mil. Its Operating Income for the three months ended in Jun. 2024 was ₩1,104.04 Mil.

Hence, Samil Pharmaceutical Co's Capex-to-Operating-Income for the three months ended in Jun. 2024 was 1.03.


Samil Pharmaceutical Co Capex-to-Operating-Income Historical Data

The historical data trend for Samil Pharmaceutical Co's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Samil Pharmaceutical Co Capex-to-Operating-Income Chart

Samil Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 2.63 82.78 12.11 3.77

Samil Pharmaceutical Co Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.85 4.19 8.11 0.25 1.03

Competitive Comparison of Samil Pharmaceutical Co's Capex-to-Operating-Income

For the Drug Manufacturers - Specialty & Generic subindustry, Samil Pharmaceutical Co's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Samil Pharmaceutical Co's Capex-to-Operating-Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Samil Pharmaceutical Co's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Samil Pharmaceutical Co's Capex-to-Operating-Income falls into.



Samil Pharmaceutical Co Capex-to-Operating-Income Calculation

Samil Pharmaceutical Co's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-24390.638) / 6471.028
=3.77

Samil Pharmaceutical Co's Capex-to-Operating-Income for the quarter that ended in Jun. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-1137.428) / 1104.037
=1.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Samil Pharmaceutical Co  (XKRX:000520) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Samil Pharmaceutical Co Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Samil Pharmaceutical Co's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Samil Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
990-1, Bangbae-dong, Seocho-Gu, Seoul, KOR, 137-060
Samil Pharmaceutical Co Ltd is engaged in manufacturing and distribution of pharmaceutical products and medicines in South Korea. Its products portfolio consists of gastrointestinal drugs such as antiulcerants, gastroprokinetic agents, digestive enzymes with nutrients and laxatives.

Samil Pharmaceutical Co Headlines

No Headlines